A Phase 3 interventional study of Part I - etoricoxib 60 mg and Part I - etoricoxib 90 mg in Spondylitis, Ankylosing, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-18.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to evaluate the efficacy and tolerability of two doses of etoricoxib compared to naproxen in the treatment of ankylosing spondylitis (AS). The primary objectives are to evaluate the improvement in Spinal Pain Intensity over 6 weeks of treatment with etoricoxib 90 mg or 60 mg compared to naproxen; and to evaluate the improvement in Spinal Pain Intensity over 6 weeks of treatment with etoricoxib 90 mg compared with etoricoxib 60 mg. Additionally the added benefit of increasing the dose of etoricoxib from 60 mg to 90 mg will be assessed in the second part of the study. The primary hypothesis is that the improvement in Spinal Pain Intensity visual analog scale (VAS) as measured by the time-weighted average (TWA) change from baseline over 6 weeks of treatment in Part I for etoricoxib 90 mg or 60 mg once daily is not inferior to naproxen 1000 mg.
533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.
This study's enrollment of 1,015 is above the median of 88 across 303 interventional studies indexed under Spondylitis, Ankylosing.
Browse Spondylitis, Ankylosing studies →Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib 60 mg in Part I and Part II
Drug: Part I - etoricoxib 60 mg · Drug: Part I - Placebo to naproxen 500 mg · Drug: Part II- etoricoxib 60 mg · Drug: Part I - Placebo to etoricoxib 90 mg · Drug: Part II - Placebo to etoricoxib 90 mg · Drug: Part II- Placebo to naproxen 500 mg
The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 60 mg in Part I and etoricoxib 90 mg in Part II
Drug: Part I - etoricoxib 60 mg · Drug: Part I - Placebo to naproxen 500 mg · Drug: Part II- etoricoxib 90 mg · Drug: Part I - Placebo to etoricoxib 90 mg · Drug: Part II- Placebo to etoricoxib 60 mg · Drug: Part II- Placebo to naproxen 500 mg
The etoricoxib 90 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 90 mg in Part I and Part II
Drug: Part I - etoricoxib 90 mg · Drug: Part I - Placebo to naproxen 500 mg · Drug: Part II- etoricoxib 90 mg · Drug: Part I - Placebo to etoricoxib 60 mg · Drug: Part II- Placebo to etoricoxib 60 mg · Drug: Part II- Placebo to naproxen 500 mg
The naproxen 1000 mg/naproxen 1000 mg treatment sequence will receive naproxen 1000 mg in Part I and Part II
Drug: Part I- naproxen 1000 mg · Drug: Part II- naproxen 1000 mg · Drug: Part I - Placebo to etoricoxib 60 mg · Drug: Part I - Placebo to etoricoxib 90 mg · Drug: Part II- Placebo to etoricoxib 60 mg · Drug: Part II - Placebo to etoricoxib 90 mg
etoricoxib 60 mg oral tablet once daily for 6 weeks
Also known as: MK-0663
etoricoxib 90 mg oral tablet once daily for 6 weeks
Also known as: Mk-0663
naproxen 500 mg oral tablet twice daily for 6 weeks
Placebo to naproxen 500 mg oral tablet twice daily for 6 weeks
etoricoxib 60 mg oral tablet once daily for 20 weeks
Also known as: MK-0663
etoricoxib 90 mg oral tablet once daily for 20 weeks
Also known as: MK-0663
naproxen 500 mg oral tablet twice daily for 20 weeks
Placebo to etoricoxib 60 mg oral tablet once daily for 6 weeks.
Placebo to etoricoxib 90 mg oral tablet once daily for 6 weeks.
Placebo to etoricoxib 60 mg oral tablet once daily for 20 weeks.
Placebo to etoricoxib 90 mg oral tablet once daily for 20 weeks.
Placebo to naproxen 500 mg orally twice daily for 20 weeks.
Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. Naproxen
Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. The time-weighted average change is calculated by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.
Time frame: Baseline and up to Week 6
Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 60 mg vs. Naproxen
Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. The time-weighted average change is calculated by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.
Time frame: Baseline and up to Week 6
Number of Participants Discontinuing Study Treatment Due to an Adverse Event
Time frame: Up to 26 weeks
Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. Etoricoxib 60 mg
Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. The time-weighted average change is calculated by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.
Time frame: Baseline and up to Week 6
Average Change From Week 6 in the Spinal Pain Intensity Over Weeks 10 and 12 in Study Part 2: Etoricoxib 60/90 mg vs. Etoricoxib 60mg (Non-responders From Part I)
Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. Average change from Week 6 in Spinal Pain Intensity (VAS) over Weeks 10 and 12 is calculated as the average Spinal pain Intensity (VAS) value over Weeks 10 and 12 minus the Spinal Pain Intensity (VAS) at Week 6.
Time frame: Week 6 to Week 10 and Week 12
| Milestone | Etoricoxib 60 mg (Part I) | Etoricoxib 90 mg (Part I) | Naproxen 1000 mg (Part I) | Etoricoxib 60 mg / 60 mg (Part II) | Etoricoxib 60 mg / 90 mg (Part II) | Etoricoxib 90 mg / 90 mg (Part II) | Naproxen 1000 mg (Part II) |
|---|---|---|---|---|---|---|---|
| Started | 702 | 156 | 157 | 0 | 0 | 0 | 0 |
| Completed | 632 | 145 | 142 | 0 | 0 | 0 | 0 |
| Not completed | 70 | 11 | 15 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 19 | 2 | 6 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 21 | 3 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 6 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 8 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 14 | 4 | 4 | 0 | 0 | 0 | 0 |
| Milestone | Etoricoxib 60 mg (Part I) | Etoricoxib 90 mg (Part I) | Naproxen 1000 mg (Part I) | Etoricoxib 60 mg / 60 mg (Part II) | Etoricoxib 60 mg / 90 mg (Part II) | Etoricoxib 90 mg / 90 mg (Part II) | Naproxen 1000 mg (Part II) |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 314 | 318 | 145 | 142 |
| Completed | 0 | 0 | 0 | 282 | 295 | 129 | 131 |
| Not completed | 0 | 0 | 0 | 32 | 23 | 16 | 11 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 10 | 9 | 3 | 5 |
| Withdrew: Adverse event | 0 | 0 | 0 | 5 | 9 | 4 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 6 | 4 | 3 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 4 | 0 | 2 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 0 | 4 | 1 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 0 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Technical problems | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. The time-weighted average change is calculated by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.
| mm VAS | Etoricoxib 90 mg | Naproxen 1000 mg |
|---|---|---|
| Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. Naproxen | -31.23 (-34.70 to -27.76) | -30.59 (-34.07 to -27.10) |
Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. The time-weighted average change is calculated by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.
| mm VAS | Etoricoxib 60 mg | Naproxen 1000 mg |
|---|---|---|
| Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 60 mg vs. Naproxen | -29.00 (-30.69 to -27.31) | -30.59 (-34.07 to -27.10) |
Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. The time-weighted average change is calculated by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.
| mm VAS | Etoricoxib 90 mg | Etoricoxib 60 mg |
|---|---|---|
| Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. Etoricoxib 60 mg | -30.51 (-33.87 to -27.15) | -28.94 (-30.58 to -27.29) |
Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. Average change from Week 6 in Spinal Pain Intensity (VAS) over Weeks 10 and 12 is calculated as the average Spinal pain Intensity (VAS) value over Weeks 10 and 12 minus the Spinal Pain Intensity (VAS) at Week 6.
| mm VAS | Etoricoxib 60 mg/ 90 mg | Etoricoxib 60 mg / 60 mg |
|---|---|---|
| Average Change From Week 6 in the Spinal Pain Intensity Over Weeks 10 and 12 in Study Part 2: Etoricoxib 60/90 mg vs. Etoricoxib 60mg (Non-responders From Part I) | -9.97 (-12.42 to -7.51) | -7.26 (-9.73 to -4.80) |
| Participants | Etoricoxib 60 mg (Part I) | Etoricoxib 90 mg (Part I) | Naproxen 1000 mg (Part I) | Etoricoxib 60 mg / 60 mg (Part II) | Etoricoxib 60 mg / 90 mg (Part II) | Etoricoxib 90 mg / 90 mg (Part II) | Naproxen 1000 mg (Part II) |
|---|---|---|---|---|---|---|---|
| Number of Participants Discontinuing Study Treatment Due to an Adverse Event | 22 | 2 | 6 | 3 | 9 | 4 | 2 |
Collected over Up to Week 30 (including up to 28 days after last dose of study drug). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Etoricoxib 60 mg / Etoricoxib 60 mg | — | 1/313 (0.3%) | 55/313 (17.6%) |
| Etoricoxib 60 mg / Etoricoxib 90 mg | — | 7/319 (2.2%) | 50/319 (15.7%) |
| Etoricoxib 90 mg / Etoricoxib 90 mg | — | 6/145 (4.1%) | 24/145 (16.6%) |
| Naproxen 1000 mg / Naproxen 1000 mg | — | 2/142 (1.4%) | 25/142 (17.6%) |
| Etoricoxib 60 mg | — | 5/70 (7.1%) | 18/70 (25.7%) |
| Etoricoxib 90 mg | — | 0/10 (0%) | 6/10 (60%) |
| Naproxen 1000 mg | — | 0/14 (0%) | 9/14 (64.3%) |
| Event | Etoricoxib 60 mg / Etoricoxib 60 mg | Etoricoxib 60 mg / Etoricoxib 90 mg | Etoricoxib 90 mg / Etoricoxib 90 mg | Naproxen 1000 mg / Naproxen 1000 mg | Etoricoxib 60 mg | Etoricoxib 90 mg | Naproxen 1000 mg |
|---|---|---|---|---|---|---|---|
| Ankylosing spondylitisMusculoskeletal and connective tissue disorders | 0/313 | 1/319 | 0/145 | 0/142 | 1/70 | 0/10 | 0/14 |
| Hip fractureInjury, poisoning and procedural complications | 0/313 | 0/319 | 0/145 | 0/142 | 1/70 | 0/10 | 0/14 |
| Cerebral infarctionNervous system disorders | 0/313 | 0/319 | 0/145 | 0/142 | 1/70 | 0/10 | 0/14 |
| Cerebrovascular accidentNervous system disorders | 0/313 | 0/319 | 0/145 | 0/142 | 1/70 | 0/10 | 0/14 |
| HeadacheNervous system disorders | 0/313 | 0/319 | 0/145 | 0/142 | 1/70 | 0/10 | 0/14 |
| ProstatitisReproductive system and breast disorders | 0/313 | 0/319 | 0/145 | 0/142 | 1/70 | 0/10 | 0/14 |
| Hypertensive crisisVascular disorders | 0/313 | 0/319 | 0/145 | 0/142 | 1/70 | 0/10 | 0/14 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/313 | 0/319 | 2/145 | 0/142 | 0/70 | 0/10 | 0/14 |
| Non-cardiac chest painGeneral disorders | 0/313 | 0/319 | 0/145 | 1/142 | 0/70 | 0/10 | 0/14 |
| AbscessInfections and infestations | 0/313 | 0/319 | 0/145 | 1/142 | 0/70 | 0/10 | 0/14 |
| Event | Etoricoxib 60 mg / Etoricoxib 60 mg | Etoricoxib 60 mg / Etoricoxib 90 mg | Etoricoxib 90 mg / Etoricoxib 90 mg | Naproxen 1000 mg / Naproxen 1000 mg | Etoricoxib 60 mg | Etoricoxib 90 mg | Naproxen 1000 mg |
|---|---|---|---|---|---|---|---|
| HypertensionVascular disorders | 18/313 | 15/319 | 8/145 | 8/142 | 4/70 | 0/10 | 2/14 |
| NauseaGastrointestinal disorders | 5/313 | 3/319 | 3/145 | 1/142 | 4/70 | 0/10 | 2/14 |
| HeadacheNervous system disorders | 10/313 | 13/319 | 9/145 | 5/142 | 4/70 | 1/10 | 1/14 |
| PalpitationsCardiac disorders | 2/313 | 0/319 | 0/145 | 0/142 | 0/70 | 1/10 | 1/14 |
| Abdominal painGastrointestinal disorders | 3/313 | 3/319 | 0/145 | 1/142 | 1/70 | 1/10 | 0/14 |
| DiarrhoeaGastrointestinal disorders | 7/313 | 8/319 | 2/145 | 4/142 | 4/70 | 1/10 | 1/14 |
| Blood pressure increasedInvestigations | 9/313 | 7/319 | 0/145 | 0/142 | 1/70 | 1/10 | 0/14 |
| DysgeusiaNervous system disorders | 0/313 | 0/319 | 3/145 | 0/142 | 0/70 | 1/10 | 1/14 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/313 | 6/319 | 1/145 | 0/142 | 0/70 | 1/10 | 0/14 |
| PruritusSkin and subcutaneous tissue disorders | 2/313 | 1/319 | 1/145 | 2/142 | 2/70 | 1/10 | 0/14 |
| Age, Continuous(Years) | Etoricoxib 60 mg | Etoricoxib 90 mg | Naproxen 1000 mg | Total |
|---|---|---|---|---|
| Mean | 45.4 ± 12.4 | 45.2 ± 11.3 | 44.5 ± 12.3 | 45.2 ± 12.2 |
| Sex: Female, Male(Participants) | Etoricoxib 60 mg | Etoricoxib 90 mg | Naproxen 1000 mg | Total |
|---|---|---|---|---|
| Female | 209 | 45 | 41 | 295 |
| Male | 493 | 111 | 116 | 720 |
| Spinal Pain Intensity(mm VAS) | Etoricoxib 60 mg | Etoricoxib 90 mg | Naproxen 1000 mg | Total |
|---|---|---|---|---|
| Mean | 76.7 ± 14.2 | 76.7 ± 15.2 | 77.0 ± 14.0 | 76.8 ± 14.3 |
No study locations are listed for this record.
Plan to share: No
Ran from Sep 2010 to primary completion in Nov 2014, 49 months.
Results were first posted in Jul 2015, 7 months after primary completion.
Of 38 industry-sponsored phase 3 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 49 months is above that.
Counting every sponsor, half of 40 studies reached it within 21 months; a quarter within 15 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etoricoxib